Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s ivonescimab is a bispecific antibody that combines the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-vascular endothelial growth factor into a single molecule. Co. also focuses on ridinilazole, its product candidate for treating patients suffering from Clostridioides difficile infection. Co.'s other product candidate, SMT-738, is in development for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae infections. We show 11 historical shares outstanding datapoints in our SMMT shares outstanding history coverage, used to compute SMMT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SMMT market cap history over the course of time is important for investors
interested in comparing SMMT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SMMT versus a peer is one thing; comparing
SMMT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SMMT can fluctuate over the course of history.
With this page we aim to empower investors researching SMMT by allowing them to research the SMMT market cap history. |
Free SMMT Email Alerts:
Video: The Importance of Market Cap
